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Abstract
Since 1990, when a hypothesis on intrauterine influences on
breast cancer risk was published, several studies have provided
supportive, indirect evidence by documenting associations of birth
weight and other correlates of the prenatal environment with breast
cancer risk in offspring. Recent results from a unique cohort of
women with documented exposure to diethylstilbestrol in utero
have provided direct evidence in support of a potential role of
pregnancy oestrogens on breast cancer risk in offspring.
In the 1980s several investigators evaluated whether prenatal
characteristics may be related to breast cancer risk in
offspring [1,2]. However, it was not until 1990 that a hypo-
thesis on roots of breast cancer in early life was articulated
[3]. Trichopoulos postulated that higher concentrations of
oestrogens in pregnancy increase the probability of
occurrence of breast cancer in daughters. The concept was
subsequently elaborated into an integrated model of the
natural history of breast cancer that accommodates most
established risk factors for this disease [4-6].
Until recently, the evaluation of whether exposure to
pregnancy oestrogens, and conceivably other mammotropic
hormones, increases breast cancer risk in offspring has relied
on correlates of pregnancy oestrogens. These correlates
include birth weight, which tends to increase with higher
pregnancy oestrogen levels; twinning, which is characterized
by higher pregnancy oestrogen levels than in singleton
pregnancies; pregnancy toxaemia, in which oestrogen levels
have been reported to be lower than those in normal
pregnancies; and first versus higher birth orders, with first
pregnancies reportedly being associated with higher levels of
oestrogens. Most, although not all, studies that evaluated the
association of these markers of pregnancy oestrogen levels
with breast cancer risk in the offspring - including
investigations into birth weight [7-9], twinning [10], preg-
nancy toxaemia [11] and birth order [12] - have been inter-
preted as suggesting that higher levels of pregnancy oestro-
gens may increase breast cancer risk in offspring.
However, investigations such as those cited above do not
directly address the possible role played by pregnancy
oestrogens. This became possible in a unique study that
made the best of a tragic natural experiment [13-15]. In 1971
the daughters of mothers prescribed diethylstilbestrol (DES),
a synthetic oestrogen that supposedly protects against
spontaneous abortion, were found to be at a dramatically
increased risk for developing clear cell carcinoma of the
vagina and cervix, in a striking demonstration of trans-
placental carcinogenesis in humans [16]. DES had been
prescribed to more than a million pregnant women in the
USA from the 1940s to the 1960s.
Since 1992, all US cohorts of DES-exposed persons for
whom there was an appropriate comparison group of
unexposed persons and for whom there was medical record
documentation of exposure (or not) to this substance are
being followed in a study supported by the US National
Cancer Institute. Slightly more than 4800 women exposed in
utero to DES and approximately 2070 unexposed women are
included in this cohort. Results concerning breast cancer in
offspring have been reported in three reports [13-15]. The
risk for developing breast cancer in the earliest report [13],
when women exposed to DES in utero were still very young
(38 years on the average), was barely 18% higher in exposed
to nonexposed women. However, the increase became
progressively greater with longer follow up.
In the most recent report [15], for breast cancer occurring at
age 40 years or older the risk was significantly higher, by
91%, in women exposed to DES in utero than in those who
were not exposed. For breast cancer at age 50 years or older
Commentary
Intrauterine exposures, pregnancy estrogens and breast cancer
risk: where do we currently stand?
Pagona Lagiou1,2
1Department of Hygiene and Epidemiology, University of Athens Medical School, 75 M. Asias Street, Goudi, GR-115 27, Athens, Greece
2Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE 171 77, Stockholm, Sweden
Corresponding author: Pagona Lagiou, pdlagiou@med.uoa.gr
Published: 14 November 2006 Breast Cancer Research 2006, 8:112 (doi:10.1186/bcr1615)
This article is online at http://breast-cancer-research.com/content/8/6/112
© 2006 BioMed Central Ltd
DES = diethylstilbestrol.Page 2 of 2
(page number not for citation purposes)
Breast Cancer Research    Vol 8 No 6 Lagiou
the corresponding excess was 200%, which again was
significant but with a wide confidence interval. The overall
pattern does not come as a surprise because breast cancer
among young women is known frequently to have genetic
roots [17], so an excess risk on account of intrauterine
exposure to oestrogens is likely to become more evident with
advancing age.
How can the evidence now be summarized? It is highly likely
that intrauterine exposures are involved in breast cancer
aetiology. The results of the studies conducted by Palmer and
coworkers [14,15] specifically point to intrauterine exposure
to oestrogens as affecting the bulk of breast cancer cases
that are not genetically determined, perhaps by increasing the
number of mammary gland stem cells and thus the risk for
malignant transformation of one of them [4,6,18]. Neverthe-
less, even if further follow up of this cohort were to confirm
the patterns already noted, a number of questions would
remain. First, are oestrogens the only relevant hormones, or
do other growth-enhancing mammotropic hormones also play
a role? Second, are growth processes in the intrauterine
environment of unique importance or just a phase in the
growth process in childhood and adolescence, as speculated
several years ago on the basis of the association of height
with breast cancer risk [19]? Third, are the described
phenomena unique to breast cancer, perhaps on account of
the fact that human mammary gland remains inactive - and
the related stem cell pool dormant - until puberty, or are they
relevant to other forms of cancer [20]?
These and perhaps other questions are important and need
to be addressed, but the recent report from Palmer and
colleagues [15] goes a long way toward documenting that
intrauterine environment is relevant to the aetiology of breast
cancer and that pregnancy oestrogens are involved in this
process. This is also an opportune time to express
appreciation to those who had the vision to establish and
pursue this important cohort.
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